|
Dr. Stephen V. Liu, well-known for his contributions to lung cancer research, is an active presence on social media, specifically X, where he shares insights, updates, and engages with the oncology community. He is the Director of Thoracic Oncology at the Georgetown Lombardi Comprehensive Cancer Center and a very active member of the International Association for the Study of Lung Cancer (IASLC) .His X activity provides a comprehensive view of the latest advancements in lung cancer treatment, the collaborative spirit in the research community, and the ongoing challenges still faced in this field. His tweets regarding clinical trials are consistently top ranked with the highest levels of engagement among the oncology community.
Dr. Liu is an avid advocate for collaboration as evidenced by his frequent interactions with other researchers and his participation in conferences and symposiums. His tweets regularly highlight the importance of these gatherings:
"Join me at Drs. @Annechiangmd and @LuisPaz_Ares in this episode of the @IASLC podcast Lung Cancer Considered as we discuss treatment for relapsed #SCLC including lurbinectedin, tarlatamab and T-cell engagers, ADCs, and biomarkers. #LCSM" Link
At events like #CIOT24 and #ELCC24, Dr. Liu shares his critical evaluations of new studies and therapies, conveying his respect for well-conducted research and his commitment to clinical advancement.
Dr. Liu frequently expresses positive sentiments when discussing the impact of new therapies and studies. For instance, his optimism shines through when positive trial results are shared:
"FDA grants accelerated approval to tarlatamab for #SCLC after chemotherapy. Tarlatamab is a DLL3 Bispecific T-cell Engager (BiTE). Approval based on DeLLphi-301 study that showed RR 40% and mDOR 9.7m. Main toxicity is cytokine release syndrome & ICANS." Link
He often acknowledges successful outcomes and the promising future of ongoing research, showcasing his positive outlook and dedication to patient outcomes.
Balanced with his optimism, Dr. Liu also does not shy away from expressing reservations. His critical side often comes forward in discussing the limitations and setbacks in the field, ensuring an honest portrayal of both successes and challenges:
.Dr Liu's criticism of the LUNAR Trial by Novocure was particularly biting. Despite the trial m
Dr. Liu does a great job engaging his peers and generating discussion around major topics in the treatment of lung cancer. this survey regarding the LAURA trial is a great example of the effectiveness of his social engagement activities.
Dr. Liu is not only a content provider but an active participant in conversations, making his X feed a lively platform for professional exchange and education:. He allows his network on X to engage with his activities at various Lung Cancer Research Meetings. Below is a great example of his interaction with patient advocate Jill Feldman regarding a global research meeting slide in Italy:
Through these interactions, he bridges the gap between academics and the broader medical community, ensuring that complex data is accessible and discussions are inclusive.
Dr. Stephen V. Liu’s online presence encapsulates the essence of a dedicated oncologist deeply invested in both the scientific and humanistic aspects of lung cancer research. His balanced engagement—celebrating successes, critically analyzing setbacks, and addressing ethical concerns—makes him a respected and influential voice within the oncological community on social media. His ability to disseminate information, foster discussions, and mentor through platforms like X demonstrates the evolving role of healthcare professionals in the digital age.
For further insights and to join the conversation, follow Dr. Stephen V. Liu on X @StephenVLiu.
Clinical Trial / Sentiment | Content |
---|---|
ADAURA POSITIVE
|
|
ADRIATIC POSITIVE
|
|
ALINA POSITIVE
|
|
CHECKMATE 816 POSITIVE
|
|
CHECKMATE 73L NEGATIVE
|
|
EVOKE-01 NEUTRAL
|
|
FLAURA2 NEUTRAL
|
|
keynote-671 NEUTRAL
|
|
KRYSTAL-12 POSITIVE
|
|
KRYSTAL-12 POSITIVE
|
|
LUNAR NEGATIVE
|
|
LUNAR NEGATIVE
|
|
MARIPOSA NEGATIVE
|
|
MARS-2 NEUTRAL
|
|
PACIFIC-2 NEUTRAL
|
|
PALOMA-3 POSITIVE
|
|
PAPILLON POSITIVE
|
|
PAPILLON NEUTRAL
|
|
PAPILLON POSITIVE
|
|
PAPILLON POSITIVE
|
|
Company | Total | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
AstraZeneca Pharmaceuticals LP |
$133,307 |
$18,733 |
$31,221 |
$24,375 |
$22,927 |
$8,903 |
$7,193 |
$19,955 |
Merck Sharp & Dohme Corporation |
$86,002 |
$0 |
$0 |
$59,252 |
$14,000 |
$12,750 |
$0 |
$0 |
F. Hoffmann-La Roche AG |
$73,689 |
$0 |
$15,180 |
$30,651 |
$1,980 |
$7,263 |
$7,161 |
$11,454 |
Takeda Pharmaceuticals U.S.A., Inc. |
$54,387 |
$0 |
$20,806 |
$9,083 |
$0 |
$8,033 |
$6,120 |
$10,346 |
AstraZeneca UK Limited |
$33,328 |
$0 |
$0 |
$19,034 |
$3,425 |
$3,425 |
$3,490 |
$3,954 |
|
|
|
|
|
Clinical Trial | Tweets | Peer Outreach | Peer Engagement |
CHECKMATE 816 | 10 | 10 | 88 |
KEYNOTE-671 | 5 | 23 | 48 |
MARIPOSA | 8 | 9 | 38 |
LAURA | 6 | 29 | 35 |
PAPILLON | 10 | 6 | 24 |